FdaApplication
NDA 207561
Identifiers
- fda_app_no: NDA207561
Properties
| Property | Value |
|---|---|
| applicant_name | GILEAD SCIENCES INC |
| application_type | NDA |
| approval_date | 2015-11-05 |
Revenue by product
GENVOYA
| Period | Revenue |
|---|---|
| Q2 2026 | $289.0M* |
| Q1 2026 | $264.0M* |
| Q4 2025 | $380.0M* |
| Q3 2025 | $377.0M* |
| Q2 2025 | $377.0M* |
| Q1 2025 | $364.0M* |
| Q4 2024 | $470.0M* |
| Q3 2024 | $449.0M* |
| Q2 2024 | $440.0M* |
| Q1 2024 | $403.0M* |
| Q4 2023 | $516.0M* |
| Q3 2023 | $503.0M* |
| Q2 2023 | $540.0M* |
| Q1 2023 | $501.0M* |
| Q4 2022 | $640.0M* |
| Q3 2022 | $600.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| GENVOYA | COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | 150MG;150MG;200MG;EQ 10MG BASE | TABLET;ORAL |
1 product